A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma.

Trial Profile

A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs A-dmDT390-anti-CD3bisFv immunotoxin (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Angimmune
  • Most Recent Events

    • 28 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 31 Dec 2015 Planned End Date changed from 1 Jul 2018 to 1 Jun 2020 as per ClinicalTrials.gov record.
    • 31 Dec 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Feb 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top